Comparison of the effect of ciprofloxacin and Tazocin® on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit

Mamoon A. Aldeyab, Carmel M. Hughes, Mary P. Kearney, Michael G. Scott, David A. McDowell, Joanne Hanley, M. Ann S. McMahon, Salah M. Elshibly, Ronald Bailie, James C. McElnay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) is a very significant agent of recalcitrant healthcare-associated infections. A major risk of acquiring such infections is thought to be modulated by the use of particular antimicrobial therapies. The aim of this research was to evaluate prospectively the impact of using either ciprofloxacin or Tazocin® (piperacillin + tazobactam) on the incidence of MRSA in an Intensive Care Unit (ICU). The 1-year (2× 6 months) cross-over study was carried out in a medium-sized (426 beds) teaching hospital. During the first 6-month period, ciprofloxacin was used as the first-line broad-spectrum antibiotic therapy of choice. During the second 6-month period, Tazocin® was used as first-line therapy. The incidence of hospital-acquired MRSA (i.e. colonised and/or infected) and rates of compliance of the ICU healthcare workers to optimal hand hygiene practices were recorded throughout the study. The study observed no statistically significant differences (P = 0.1) between MRSA incidence rates in the ICU during the ciprofloxacin (4.4/1000 bed-days) or Tazocin® (11.4/1000 bed-days) arms of the study. Interestingly, observing healthcare workers' hand hygiene practices throughout the entire study showed that healthcare workers adhered to these practices 59.2% of the time during the ciprofloxacin arm and 66.0% during the Tazocin® arm. The low incidence rates within the unit demonstrated the importance of infection control in limiting the spread of MRSA despite the extensive use of antibiotics in a high-risk setting.

Original languageEnglish
Pages (from-to)499-504
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume32
Issue number6
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Methicillin
Ciprofloxacin
Intensive Care Units
Staphylococcus aureus
Incidence
Hand Hygiene
Delivery of Health Care
Anti-Bacterial Agents
Infection Control
Cross Infection
Teaching Hospitals
Cross-Over Studies
Therapeutics
tazobactam drug combination piperacillin
Infection
Research

Cite this

Aldeyab, Mamoon A. ; Hughes, Carmel M. ; Kearney, Mary P. ; Scott, Michael G. ; McDowell, David A. ; Hanley, Joanne ; McMahon, M. Ann S. ; Elshibly, Salah M. ; Bailie, Ronald ; McElnay, James C. / Comparison of the effect of ciprofloxacin and Tazocin® on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit. In: International Journal of Antimicrobial Agents. 2008 ; Vol. 32, No. 6. pp. 499-504.
@article{872559d98d6142adaf655f0c78ca94de,
title = "Comparison of the effect of ciprofloxacin and Tazocin{\circledR} on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit",
abstract = "Meticillin-resistant Staphylococcus aureus (MRSA) is a very significant agent of recalcitrant healthcare-associated infections. A major risk of acquiring such infections is thought to be modulated by the use of particular antimicrobial therapies. The aim of this research was to evaluate prospectively the impact of using either ciprofloxacin or Tazocin{\circledR} (piperacillin + tazobactam) on the incidence of MRSA in an Intensive Care Unit (ICU). The 1-year (2× 6 months) cross-over study was carried out in a medium-sized (426 beds) teaching hospital. During the first 6-month period, ciprofloxacin was used as the first-line broad-spectrum antibiotic therapy of choice. During the second 6-month period, Tazocin{\circledR} was used as first-line therapy. The incidence of hospital-acquired MRSA (i.e. colonised and/or infected) and rates of compliance of the ICU healthcare workers to optimal hand hygiene practices were recorded throughout the study. The study observed no statistically significant differences (P = 0.1) between MRSA incidence rates in the ICU during the ciprofloxacin (4.4/1000 bed-days) or Tazocin{\circledR} (11.4/1000 bed-days) arms of the study. Interestingly, observing healthcare workers' hand hygiene practices throughout the entire study showed that healthcare workers adhered to these practices 59.2{\%} of the time during the ciprofloxacin arm and 66.0{\%} during the Tazocin{\circledR} arm. The low incidence rates within the unit demonstrated the importance of infection control in limiting the spread of MRSA despite the extensive use of antibiotics in a high-risk setting.",
keywords = "Antibiotic resistance, Hospital-acquired MRSA, Infection control practices",
author = "Aldeyab, {Mamoon A.} and Hughes, {Carmel M.} and Kearney, {Mary P.} and Scott, {Michael G.} and McDowell, {David A.} and Joanne Hanley and McMahon, {M. Ann S.} and Elshibly, {Salah M.} and Ronald Bailie and McElnay, {James C.}",
year = "2008",
month = "12",
doi = "10.1016/j.ijantimicag.2008.06.021",
language = "English",
volume = "32",
pages = "499--504",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "6",

}

Comparison of the effect of ciprofloxacin and Tazocin® on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit. / Aldeyab, Mamoon A.; Hughes, Carmel M.; Kearney, Mary P.; Scott, Michael G.; McDowell, David A.; Hanley, Joanne; McMahon, M. Ann S.; Elshibly, Salah M.; Bailie, Ronald; McElnay, James C.

In: International Journal of Antimicrobial Agents, Vol. 32, No. 6, 12.2008, p. 499-504.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the effect of ciprofloxacin and Tazocin® on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit

AU - Aldeyab, Mamoon A.

AU - Hughes, Carmel M.

AU - Kearney, Mary P.

AU - Scott, Michael G.

AU - McDowell, David A.

AU - Hanley, Joanne

AU - McMahon, M. Ann S.

AU - Elshibly, Salah M.

AU - Bailie, Ronald

AU - McElnay, James C.

PY - 2008/12

Y1 - 2008/12

N2 - Meticillin-resistant Staphylococcus aureus (MRSA) is a very significant agent of recalcitrant healthcare-associated infections. A major risk of acquiring such infections is thought to be modulated by the use of particular antimicrobial therapies. The aim of this research was to evaluate prospectively the impact of using either ciprofloxacin or Tazocin® (piperacillin + tazobactam) on the incidence of MRSA in an Intensive Care Unit (ICU). The 1-year (2× 6 months) cross-over study was carried out in a medium-sized (426 beds) teaching hospital. During the first 6-month period, ciprofloxacin was used as the first-line broad-spectrum antibiotic therapy of choice. During the second 6-month period, Tazocin® was used as first-line therapy. The incidence of hospital-acquired MRSA (i.e. colonised and/or infected) and rates of compliance of the ICU healthcare workers to optimal hand hygiene practices were recorded throughout the study. The study observed no statistically significant differences (P = 0.1) between MRSA incidence rates in the ICU during the ciprofloxacin (4.4/1000 bed-days) or Tazocin® (11.4/1000 bed-days) arms of the study. Interestingly, observing healthcare workers' hand hygiene practices throughout the entire study showed that healthcare workers adhered to these practices 59.2% of the time during the ciprofloxacin arm and 66.0% during the Tazocin® arm. The low incidence rates within the unit demonstrated the importance of infection control in limiting the spread of MRSA despite the extensive use of antibiotics in a high-risk setting.

AB - Meticillin-resistant Staphylococcus aureus (MRSA) is a very significant agent of recalcitrant healthcare-associated infections. A major risk of acquiring such infections is thought to be modulated by the use of particular antimicrobial therapies. The aim of this research was to evaluate prospectively the impact of using either ciprofloxacin or Tazocin® (piperacillin + tazobactam) on the incidence of MRSA in an Intensive Care Unit (ICU). The 1-year (2× 6 months) cross-over study was carried out in a medium-sized (426 beds) teaching hospital. During the first 6-month period, ciprofloxacin was used as the first-line broad-spectrum antibiotic therapy of choice. During the second 6-month period, Tazocin® was used as first-line therapy. The incidence of hospital-acquired MRSA (i.e. colonised and/or infected) and rates of compliance of the ICU healthcare workers to optimal hand hygiene practices were recorded throughout the study. The study observed no statistically significant differences (P = 0.1) between MRSA incidence rates in the ICU during the ciprofloxacin (4.4/1000 bed-days) or Tazocin® (11.4/1000 bed-days) arms of the study. Interestingly, observing healthcare workers' hand hygiene practices throughout the entire study showed that healthcare workers adhered to these practices 59.2% of the time during the ciprofloxacin arm and 66.0% during the Tazocin® arm. The low incidence rates within the unit demonstrated the importance of infection control in limiting the spread of MRSA despite the extensive use of antibiotics in a high-risk setting.

KW - Antibiotic resistance

KW - Hospital-acquired MRSA

KW - Infection control practices

UR - http://www.scopus.com/inward/record.url?scp=55249117927&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.06.021

DO - 10.1016/j.ijantimicag.2008.06.021

M3 - Article

VL - 32

SP - 499

EP - 504

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 6

ER -